Emily Alva Net Worth

The estimated Net Worth of Emily Peterson Alva is at least 599 千$ dollars as of 29 June 2024. Ms. Alva owns over 6,104 units of Amneal Pharmaceuticals Inc stock worth over 240,492$ and over the last 6 years she sold AMRX stock worth over 0$. In addition, she makes 358,843$ as Independent Director at Amneal Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Alva AMRX stock SEC Form 4 insiders trading

Emily has made over 12 trades of the Amneal Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 6,104 units of AMRX stock worth 51,029$ on 29 June 2024.

The largest trade she's ever made was exercising 80,128 units of Amneal Pharmaceuticals Inc stock on 9 May 2023 worth over 669,870$. On average, Emily trades about 13,898 units every 76 days since 2018. As of 29 June 2024 she still owns at least 28,767 units of Amneal Pharmaceuticals Inc stock.

You can see the complete history of Ms. Alva stock trades at the bottom of the page.

Emily Alva biography

Emily Peterson Alva serves as Independent Director of the Company. Ms. Alva is a financial, strategic and business advisor to senior executives, founders and corporate boards of directors, and has focused on private company advisory projects and family office investing since 2013. Prior to that time, Ms. Alva spent more than 15 years at Lazard as a senior mergers & acquisitions investment banker advising industry leading companies. Ms. Alva’s extensive advisory and transaction work covers multiple industries with a primary sector focus and expertise in healthcare. While at Lazard, Ms. Alva held leadership roles, both with clients and internally. She advised some of Lazard’s most important clients over many years, and was one of the youngest bankers promoted to Managing Director at the firm. During her Lazard tenure, Ms. Alva was selected for the Council on Foreign Relations’ Corporate Leaders Program, which recognizes accomplished professionals on a senior management track and links business leaders with decision makers in government and academia. Prior to joining Lazard, Ms. Alva worked at a development stage company focused on engineering-based solutions to improve industrial waste processing systems. More recently, Ms. Alva has served as a Board Member and Treasurer for the Alumnae Board of Directors of Barnard College. Ms. Alva received a BA in Economics from Barnard College, Columbia University

What is the salary of Emily Alva?

As the Independent Director of Amneal Pharmaceuticals Inc, the total compensation of Emily Alva at Amneal Pharmaceuticals Inc is 358,843$. There are 9 executives at Amneal Pharmaceuticals Inc getting paid more, with Andrew Boyer having the highest compensation of 3,113,080$.

How old is Emily Alva?

Emily Alva is 45, she's been the Independent Director of Amneal Pharmaceuticals Inc since 2018. There are 19 older and 2 younger executives at Amneal Pharmaceuticals Inc. The oldest executive at Amneal Pharmaceuticals Inc is Shlomo Yanai, 67, who is the Independent Director.

What's Emily Alva's mailing address?

Emily's mailing address filed with the SEC is CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN, , 4 Ireland.

Insiders trading at Amneal Pharmaceuticals Inc

Over the last 6 years, insiders at Amneal Pharmaceuticals Inc have traded over 867,197,480$ worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth 12,997,905$ . The most active insiders traders include Gp A, Llcbonderman Davidcou...、Holdings, Llc Aphc、International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of 3,857,739$. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth 491,654$.

What does Amneal Pharmaceuticals Inc do?

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Complete history of Ms. Alva stock trades at Alkermes plc、Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Inc executives and stock owners

Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Andrew Boyer,
  Executive Vice President - Commercial Operations
• Chintu Patel R.Ph, R.Ph.,
  Co-Founder, Co-CEO & Director
• Nikita Shah,
  Chief Human Resource Officer, Senior Vice President
• Andrew S. Boyer,
  Exec. VP & Chief Commercial Officer of Generics
• Anastasios G. Konidaris,
  Exec. VP & CFO
• Joseph Todisco MBA,
  Exec. VP & Chief Commercial Officer of Specialty
• Nikita Shah,
  Exec. VP and Chief HR Officer & Strategic Planning Officer
• J. Kevin Buchi,
  Independent Director
• Ted Nark,
  Independent Director
• Emily Alva,
  Independent Director
• Gautam Patel,
  Director
• Chintu Patel,
  Co-Chief Executive Officer, Co-Founder, Director
• Chirag Patel,
  President, Co-Chief Executive Officer, Director
• Paul Meister,
  Independent Chairman of the Board
• Shlomo Yanai,
  Independent Director
• John Kiely,
  Independent Director
• Jeffrey George,
  Independent Director
• Chintu Patel R.Ph., R.Ph,
  Co-Founder, Co-CEO & Director
• Chirag K. Patel,
  Co-Founder, Co-CEO, Pres & Director
• Joseph Todisco,
  Senior Vice President - Specialty Commercial
• Apurva Saraf,
  Senior Vice President - Corporate Development
• Joseph Greer,
  Senior Vice President - Global Quality Management
• Stephen Manzano,
  Senior Vice President, General Counsel & Corporate Secretary
• Sanjay Jain,
  President - India
• Anastasios Konidaris,
  Chief Financial Officer, Senior Vice President
• Jason B. Daly Esq.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Dr. Nikunj Patel,
  Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
• Sanjiv Patel,
  Sr. VP of Operations
• Stephen J. Manzano,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Anthony DiMeo,
  Sr. Director of Investor Relations
• Sheldon Hirt,
  SVP, GC & Corp. Sec.
• Jean Selden Greene,
  Director
• Holdings, Llc Aphc,
  10% owner
• Robert L Burr,
  Director
• Bryan M. Reasons,
  CFO
• Robert A Stewart,
  President and CEO
• Dharmendra Rama,
  Director
• Janet S. Vergis,
  Director
• Peter R Terreri,
  Director
• Paul Bisaro,
  Executive Chairman
• David A Buchen,
  SVP, Chief Legal Officer
• Todd P. Branning,
  SVP and CFO
• Pradeep Bhadauria,
  SVP, Chief Scientific Officer
• International Ltd Fosun,
  10% owner
• Gustavo Pesquin,
  See Remarks
• Gp A, Llcbonderman Davidcou...,
  
• Tasos Konidaris,
  Executive Vice President & CFO
• Jason B. Daly,
  SVP, Chief Legal Officer
• Deborah M. Autor,
  Director
• Dipan Patel,
  
• Tushar Bhikhubhai Patel,
  10% owner